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Background: Adherence to antiretroviral treatment (ART) is important to achieve treatment 
success in human immunodeficiency virus (HIV)-infected patients. Most HIV clinics apply the 
patient self-report (PSR) method. However, the reliability of this method in experienced HIV 
patients remains questionable.
Purpose: To validate the PSR method for measuring adherence to ART using lamivudine (3TC) 
plasma concentrations in experienced HIV patients.
Methods: The study was conducted in Dar Es Salaam and involved 220 patients who were 
receiving ART services at HIV clinics for more than 12 months. Self-reported adherence 
information to ART was obtained on the day of HIV clinic visit. The patients were asked to 
mention the number of doses missed within the past 7 days. In addition, blood samples (2 mL) 
were collected from each patient on the same day. The blood samples were determined for 3TC 
plasma concentrations. The target 3TC plasma concentration as indicator concentration for 
adherent patients was determined in 20 patients who took their evening dose of antiretrovirals 
under supervision. The blood from these patients was drawn 3 hours after drug administration.
Results: Complete drug levels of 3TC and self-reported adherence data was obtained in 200 
treatment-experienced HIV patients. Lamivudine plasma concentrations obtained in these 
patients ranged between 0.02–17.36 µg/mL. The mean time from dose administration to 
blood drawing was 3.1 ± 1.2 hours with coefficient of variation .39%. The mean 3TC plasma 
concentration obtained in 20 patients who took their antiretroviral dose under supervision was 
found to be 0.67 ± 0.46 µg/mL, range 0.25–2.33 µg/mL. As many as 82.5% of experienced HIV 
patients had PSRs in agreement with their 3TC plasma concentrations.
Conclusion: PSR adherence is still a valid method for ascertaining adherence to ART in 
treatment-experienced HIV patients.
Keywords: patient self-report, adherence, experienced HIV patients, lamivudine plasma 
concentrations
Introduction
Adherence to antiretroviral treatment (ART) has been demonstrated to reduce human 
immunodeficiency virus (HIV)-1 RNA, elevate CD4 cell counts, decrease morbidity and 
mortality due to acquired immunodeficiency syndrome (AIDS), and improve quality of 
life.1 Studies have shown that for successful ART, adherence to dosage regimen should 
be $95%.1–3 However, there are many factors which contribute to poor ART adher-
ence, such as complexity of dosing schedule, strict dietary restrictions, drug toxicity, 
pill burden, forgetting, and poor drug supply chain.4–8 Nonadherence to ART may lead Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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to suboptimal drug levels with possible therapeutic failure, 
deterioration of the immune system, and/or emergence of 
medicine-resistant HIV strains.1–3
Estimates of nonadherence to ART have varied widely, 
depending on the method of measurement, definition of non-
adherence, the population studied, and the time over which 
adherence was monitored. There are various approaches to 
measure adherence, ranging from patient self-report (PSR), 
physician assessments, electronic monitoring, pill count, and 
prescription-refill days.9–11 Determination of antiretroviral drug 
level has been recently exploited as an alternative method for 
measuring adherence to ART.9,10 Other methods include visual 
analog scale; viral load HIV-1 RNA; and macrocytosis, defined 
as mean corpuscular volume measurement, in patients under-
going stavudine- and zidovudine-containing regimen.12–14
Most HIV clinics in low- and middle-income countries, 
apply PSR as a routine method for measuring adherence in 
ART patients. The PSR method is simpler and less costly 
compared with other subjective and nonsubjective methods. 
PSR does not require expensive bioanalytical techniques and 
highly skilled personnel. However, it has been reported that 
the PSR method can lead to an overestimation of adherence 
in treatment-experienced HIV patients.6–10 In addition to 
lacking a standardized instrument for universal use in routine 
clinical practice,15–19 the validity of PSR in experienced HIV 
patients in developing countries may be questionable. This 
study reports the extent of validity of the PSR method in 
measuring adherence to ART in experienced HIV patients 
in Tanzania.
Materials and methods
study site
This was a cross-sectional study involving 220 HIV-infected 
patients receiving ART at Mwananyamala and Muhimbili 
HIV clinics located in Dar Es Salaam. The study took place 
between July and December 2010. Approval to conduct the 
study was granted by Muhimbili University of Health and 
Allied Sciences (MUHAS) Ethics Committee.
enrollment of subjects
Nurse counselors working at the HIV clinics were trained as 
research assistants. They were also involved in the identifi-
cation of files of eligible patients for inclusion in the study. 
Initially, 400 patients were purposely selected and the major 
inclusion criterion was the receiving of lamivudine (3TC)-
based ART for more than 12 months and continued atten-
dance at the HIV clinics for care and treatment. Nurses and 
counselors at each HIV clinic were involved in identification 
of those patients who were assessed by HIV clinicians and 
found to be eligible for the study. Patient selection was based 
on the “first-in, first-taken” principle, as long as the patient 
met the inclusion criteria. Out of 400 patients, 220 patients 
who consented to participate to the study on the day of 
clinic visitation were selected. The drug combination given 
to patients was zidovudine/stavudine + 3TC + nevirapine/
efavirenz. The research assistants documented all available 
data from patients’ files in line with routine measurements.
Collection of adherence information  
from patients
Eligible patients were asked by the research assistants to 
report the exact number and date of the doses they had 
missed in the past 7 days, as is done routinely in HIV   clinics 
in Tanzania. They were also asked to indicate the hour at 
which they ingested the last ARV dose before presenting to 
the clinic. In addition, blood samples were collected from 
each patient. A single venous blood sample (2 mL) was 
drawn into an ethylenediaminetetraacetic acid tube. The 
time interval between the last ARV dose intake and blood 
sampling was documented. The patients were not aware of 
the study before attending their consultation and therefore 
did not know that they were having blood drawn to measure 
3TC plasma levels. All blood samples were single samples 
obtained just after undergoing medical examinations. The 
blood samples were centrifuged immediately at 1000 g to 
obtain plasma. The obtained plasma samples were kept 
at −80°C until drug assay.
The study determined the indicator (target) 3TC plasma 
concentration in 20 separate patients who had also been on 
ART for more than 12 months. Since on average, a patient 
spent 3 hours at the HIV clinic before blood withdrawal,     
analogously, blood was drawn from these patients 3 hours 
after taking their ARV evening dose under supervision. The 
blood samples were processed to obtain plasma and stored 
until drug assay, as described above.
Determination of ARV in blood samples
Lamivudine plasma concentrations were determined by using 
a high-performance liquid chromatography method published 
by Zhou and Sommadossi with minor modifications.19 Sample 
analysis was carried out in the MUHAS–Sida (Swedish 
  International Development Cooperation Agency) Bioana-
lytical   Laboratory, Unit of Pharmacology and Therapeutics, 
School of Pharmacy, MUHAS in Dar Es Salaam, Tanzania. 
Prior to running the samples from the study patients, the 
method was validated with respect to intra- and interday Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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  precision and accuracy. The intra- and interday precision rates 
were always ,10% and sample recovery was consistently 
between 90%–110% of the spiked samples, thus indicating 
the accuracy and suitability of the analytical method used.
Data analysis
To verify the accuracy of the PSR method in treatment-
  experienced HIV patients, the proportion of patients whose 
self-reported responses were in agreement with the deter-
mined plasma concentrations was calculated. Table 1 reflects 
the plasma concentrations obtained in 20 patients who 
took their evening ARV dose under supervision. The mean 
3TC plasma concentration determined from blood samples 
drawn 3 hours after drug intake in these supervised patients 
was 0.67 ± 0.46 µg/mL (0.21–1.13 µg/mL) and ranged 
from 0.25 to 2.33 µg/mL. Therefore, all patients with 3TC 
plasma concentrations $0.21–2.33 µg/mL were taken as 
adherent as long as they stated so when interviewed by the 
research assistant. To confirm the existence of a correlation 
between PSR and drug levels in some patients, the following 
information was sought: those who reported missing some 
doses and had 3TC plasma   concentrations ,0.21 µg/mL; 
those who had plasma concentrations within the predeter-
mined range and reported adhering well to the recommended 
dosing regimen; and those who had higher levels of 3TC and 
reported taking two ARV doses on the morning of the day they 
attended the HIV clinic. These groups were regarded as hav-
ing PSR corresponding with obtained plasma drug levels.
Results
The patient population was predominantly (65%) female with 
a mean age of 49 ± 5 years.
The mean time (data not shown) from dose administra-
tion to blood drawing was 3.1 ± 1.2 hours with coefficient of 
variation (CV) 39%. Some demographic data, such as age, 
sex, weight, height, and concomitant therapy, were included 
in patient files, but in most files these data were missing.
Table 1 reflects the 3TC plasma concentrations obtained 
from 20 patients who took 3TC-based antiretroviral therapy 
(ART) in the evening under supervision and had their blood 
drawn 3 hours after drug intake. The mean 3TC plasma con-
centrations obtained from these patients was 0.67 ± 0.46 µg/
mL (0.21–1.13 µg/mL) and ranged from 0.25 to 2.33 µg/mL 
with CV 69%.
Complete drug levels of 3TC and PSR-adherence data 
were obtained in 200 out of 220 study patients.   Figure 1 shows 
the distribution of 200 patients with respect to 3TC plasma 
concentrations. The concentrations have been   categorized 
into three groups: (1) those below the cut-off point 
of ,0.21 µg/mL; (2) those within the target predetermined 
range −0.21 to 2.33 µg/mL; (3) and those .2.33 µg/mL.
Lamivudine plasma concentrations obtained in these 
patients ranged between 0.02 and 17.36 µg/mL (CV . 60%). 
Self-reported adherence indicated that, out of 200 patients 
whose plasma samples were analyzed for 3TC concentrations, 
5% (10/200) reported missing two to three doses in the past 
7 days, including the day they visited the clinic, and their 
plasma concentrations were ,0.21 µg/mL. There were six 
other patients who reported not missing any dose in the past 
7 days but had 3TC plasma concentrations below the level 
required for adherent patients. Three patients reported tak-
ing two doses of ARV in the morning and had 3TC plasma 
concentrations .2.33 µg/mL.
The number of patients whose self-reported responses 
were in agreement with the determined plasma concentra-
tions was calculated as follows:
1.  Patients whose 3TC plasma concentrations were found 
to lie within the predetermined target concentration 
(0.21–1.13 µg/mL) obtained in 20 supervised patients.
Table 1 Predetermined lamivudine (3TC) plasma concentrations in 
20 patients who took lamivudine-based adherence to antiretroviral 
treatment under supervision and blood collected 3 hours after 
drug intake
Patient 3TC plasma concentrations  
3 hours after drug intake in μg/mL
1 0.47
2 0.39
3 0.79
4 0.58
5 0.67
6 2.33
7 0.35
8 0.64
9 0.42
10 0.25
11 0.45
12 0.49
13 1.25
14 0.49
15 0.55
16 0.58
17 1.02
18 0.39
19 0.90
20 0.48
Mean 0.67
Range 0.25–2.33
sD 0.46
CV 69%
Abbreviations: SD, standard deviation; CV, coefficient of variation.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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2.  Patients who reported not missing any dose and their 3TC 
plasma concentrations were found to be .1.13 µg/mL 
but ,2.33 µg/mL (1.13–2.33 µg/mL).
3.  Patients who reported missing ARV doses and also had 3TC 
plasma concentrations ,0.21 µg/mL.
Table 2 summarizes the distribution of the 200 study 
patients in relation to PSR adherence and 3TC plasma 
concentration. The proportion of HIV-treated patients 
whose self-reported responses were in agreement with the 
determined plasma concentrations is also demonstrated 
in Figure 2. As many as 82.5% of patients (165) had PSR 
responses in agreement with their 3TC plasma concentra-
tions (Table 2).
Discussion
The study has determined the validity of PSR adherence to 
ART in experienced HIV patients in a low-income country. 
Lamivudine plasma concentrations were used as indicator 
of adherence in the study patients. The quantified 3TC 
plasma levels are grouped as reflected in Figure 1. Lami-
vudine plasma concentrations obtained in these patients 
ranged between 0.02 and 17.36 µg/mL (CV . 60%). 
There was high variation of 3TC plasma concentrations 
obtained among the study patients. The results are consistent 
with those obtained by Moore et al and Panhard et al.20,21   
The large variation of 3TC plasma concentrations among 
patients may be partly explained by the different hours at 
which the patients took their morning ARV doses before 
blood was drawn by the phlebotomist. It could also be 
explained by variability of body weights and heights (body 
mass index) and renal conditions among patients. Unfor-
tunately, the study clinic did not register the body mass 
index of most patients, and none of the patients had a serum 
creatinine assessment to determine renal performance. The 
study used only the data available in patient files in line with 
what is done routinely in Tanzanian clinics. Lamivudine is a 
prodrug that undergoes phosphorylation when catalyzed by 
intracellular kinases to form 3TC-5′-triphosphate, the active 
metabolite that prevents viral replication.23 Variation in 3TC 
disposition and, subsequently, plasma concentrations among 
patients could therefore depend on a patient’s individual 
capacity to phosphorylate the parent drug. Nevertheless, 
3TC is renally excreted and, recently, a low 3TC renal clear-
ance was demonstrated in patients who had impaired renal 
functions.24,25 Lamivudine has very short elimination half-
life of 3–4 hours21,22 and this may also have contributed to 
the large variation in the drug plasma concentrations among 
individual patients.
In this study, it was shown that there was discrepancy 
between the obtained drug plasma concentrations and 
3%
8%
89%
<0.21 µg/mL
>2.33 µg/mL
0.21–2.33 µg/mL
Figure 1 Percentage distribution of patients in relation to obtained lamivudine (3TC) plasma concentrations.
Table 2 Proportion of patients (number in brackets) in relation to patient self-report (PsR) and lamivudine (3TC) plasma concentration 
agreement (n = 200)
3TC plasma concentration  
in μg/mL
Proportion of patients with agreement  
between 3TC concentration and PSR
Proportion of patients with disagreement   
between 3TC concentration and PSR
,0.21 µg/mL 5 (10) 3 (6)
0.21–1.13 51 (102) 3 (6)
.1.13–2.33 µg/mL 25 (50) 5 (10)
.2.33 µg/mL 1.5 (3) 6.5 (13)
Total 82.5 (165) 17.5 (35)Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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patient self-reported drug intake in about 18% of patients. 
Although the proportion of nonadherent patients in the 
study was found to be low, it is still important to validate 
the PSR method regularly to reinforce its effectiveness, 
particularly in treatment-experienced HIV patients in 
low- and middle-income countries. Overall results show 
that there was good adherence in the patients studied. 
Several factors could explain the good adherence obtained 
during the study; for instance, free access to ARV drugs, 
the then-effective ARV procurement system, and adequate 
counseling of eligible patients.
The study applied 3TC plasma concentrations as a   validity 
marker of PSR. However, it is still debatable whether the 
best drug of choice, as a marker of adherence, should have 
short or long half-life. Those in support of short half-life 
drugs argue that missing a single dose of such a drug will 
lead to a detectable change in drug plasma concentration, 
as opposed to drugs with long half-life. As for drugs 
with a long half-life, a single missed dose may not be 
detectable, especially if the steady state plasma concentration 
had already been attained. Recently, Segeral et al applied plasma 
concentrations of efevirenz and nevirapine (both have long half-
lives) to determine adherence in Cambodian patients undergoing 
first-line World Health Organization-recommended HAART; 
the results obtained were consistent with those obtained by other   
methods.12
Conclusion
This study has demonstrated good agreement between 
PSR adherence and 3TC plasma concentrations in 
over 80% of the study patients. It can be concluded 
that the PSR-adherence method is still reliable for 
measuring adherence in patients undergoing ART, 
including experienced HIV patients in HIV clinics in   
Tanzania.
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